Lifitegrast ophthalmic solution 0.05% (Xiidra, Shire) has demonstrated positive results for the treatment of the signs and symptoms of dry eye disease. Eye dryness scores for some patients have improved after two weeks of treatment with the topical drop.
The time we are spending on digital devices is on the rise, and it’s unlikely to slow down any time soon. With more and more apps, games, and social media options, we have all become more dependent on smartphones, tablets, and other electronic devices.
Ophthalmologists have been waiting more than a decade for a new treatment option for their dry eye patients—and the anticipation is finally over. Lifitegrast ophthalmic solution 5% (Xiidra, Shire Ophthalmics) is a twice-daily eye drop solution and is the only FDA-approved drug indicated to treat the signs and symptoms of dry eye disease, according to the company.